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Abstract
Background: Innate immunity is considered the first line of host defense and microglia presumably
play a critical role in mediating potent innate immune responses to traumatic and infectious
challenges in the human brain. Fundamental impairments of the adaptive immune system in glioma
patients have been investigated; however, it is unknown whether microglia are capable of innate
immunity and subsequent adaptive anti-tumor immune responses within the immunosuppressive
tumor micro-environment of human glioma patients. We therefore undertook a novel
characterization of the innate immune phenotype and function of freshly isolated human glioma-
infiltrating microglia (GIM).
Methods: GIM were isolated by sequential Percoll purification from patient tumors immediately
after surgical resection. Flow cytometry, phagocytosis and tumor cytotoxicity assays were used to
analyze the phenotype and function of these cells.
Results: GIM expressed significant levels of Toll-like receptors (TLRs), however they do not
secrete any of the cytokines (IL-1β, IL-6, TNF-α) critical in developing effective innate immune
responses. Similar to innate macrophage functions, GIM can mediate phagocytosis and non-MHC
restricted cytotoxicity. However, they were statistically less able to mediate tumor cytotoxicity
compared to microglia isolated from normal brain. In addition, the expression of Fas ligand (FasL)
was low to absent, indicating that apoptosis of the incoming lymphocyte population may not be a
predominant mode of immunosuppression by microglia.
Conclusion: We show for the first time that despite the immunosuppressive environment of
human gliomas, GIM are capable of innate immune responses such as phagocytosis, cytotoxicity and
TLR expression but yet are not competent in secreting key cytokines. Further understanding of
these innate immune functions could play a critical role in understanding and developing effective
immunotherapies to malignant human gliomas.
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Background
Malignant gliomas are the most common type of primary
brain tumors and glioblastoma multiforme accounts for
more than 50% of all intracranial gliomas [1]. These
tumors are extremely aggressive and are characterized by
diffuse infiltration of the brain parenchyma, recurrent
growth, and an extremely poor prognosis for survival.
Although glioblastoma multiforme is immunogenic [2-
4], immune-mediated eradication does not occur, and
attempts at immunotherapy directed against brain tumors
have been minimally successful thus far [5-7]. Previously
characterized impairments in glioma immunity have
included low peripheral lymphocyte counts, reduced
delayed type hypersensitivity reactions to recall antigens,
impaired mitogen-induced blastogenic responses by
peripheral blood mononuclear cells (PBMCs), and
increased CD8+ suppressor T cells [8]. Adaptive immune
responses are noticeably deficient, with diminished
responsiveness of peripheral T cells associated with
impaired early transmembrane signaling through the T-
cell receptor/CD3 complex [9]. In addition, diminished
induction of immunoglobulin synthesis by B cells in vitro
from the peripheral blood of patients with intracranial
tumors appears to be related to diminished T-helper activ-
ity [10]. Although immune impairments have been iden-
tified within the adaptive arm, few studies have examined
for potential deficits in the innate arm, especially within
the context of immunosuppressed glioma patients.
Innate immunity is the initial antigen-nonspecific
response that results in the rapid production of effector
cytokines and is one of the prerequisites for triggering
effective adaptive antitumor immune responses. Soluble
factors produced by gliomas, such as immunosuppressive
cytokines (e.g., transforming growth factor [TGF-β ] and
interleukin [IL-10]), presumably impair other cells partic-
ipating in innate immunologic responses. Microglia are
the most prominent immune cell within the CNS, how-
ever, it is not known whether microglia, within the immu-
nosuppressive tumor environment, are capable of
activated or functional innate immune responses. Micro-
glia are unique to the central nervous system (CNS) and
account for as much as 20% of the non-neuronal cell pop-
ulation [11]. Microglia are defined as being CD11b/
c+CD45low, macrophages as CD11b/c+CD45high, and lym-
phocytes as CD11b/c-CD45high[12]. There is not a distinct
universally accepted histological marker to distinguish
macrophages from microglia. However, macrophages are
believed to be activated microglia within the CNS. Rodent
studies have shown that microglia play a critical effector
role in rapidly responding to certain autoimmune and
viral infections [13]. Microglia are thought to be capable
of phagocytosis, cytotoxicity, and other pro-inflammatory
innate effector functions [14]. The cells of the innate
immune system, especially macrophages, use Toll-like
receptors (TLRs) to recognize microbial or non-self fac-
tors, such as pathogen-associated molecular patterns.
TLRs are not constitutively expressed in the brain paren-
chyma [15], but cultured primary murine microglia cells
express mRNA encoding TLRs, which are strongly acti-
vated after stimulation with their specific agonists
(lipopolysaccharide (LPS) (TLR-4), peptidoglycan (TLR-
2), dsRNA (TLR-3), or CpG motifs (TLR-9)) [16]. Signal-
ing through these receptors is coupled to gene transcrip-
tion processes and has powerful immunomodulatory
effects that can result in the activation of anti-tumor
immune responses. Murine microglia have been shown to
express the mRNA for all TLRs (TLR1-9) [13]. However,
these microglia cell lines have been propagated exten-
sively in culture and thus their phenotype and function
could be markedly altered from the characteristics that
they would normally have in situ.
The soluble expression of FasL fails to induce inflamma-
tory responses. In contrast, when FasL is expressed on the
surface of tumor cells, neutrophil-mediated inflammation
is triggered initiating a vigorous innate immune response
[17,18]. The complex immunological role of FasL has
been confounded by a recent report that tumor expression
of FasL impairs NK activation [19]. Expression of FasL has
been shown to maintain immune privilege though induc-
ing apoptosis of infiltrating Fas positive effector T cells. In
the murine G26 model system, 50% of the total FasL-pos-
itive expression in intracranial tumors was accounted for
by microglia, and neutralization of FasL resulted in a sig-
nificant increase in the number of tumor-infiltrating lym-
phocytes [20]. This would indicate that microglia may
play a role in down regulating innate immune responses
within the CNS.
In this study, for the first time, we have characterized the
innate immune phenotype and function of microglia iso-
lated from human glioma tissue immediately after surgi-
cal resection. Using sequential Percoll density gradients,
the purity of GIM was determined on the basis of previ-
ously established CD11b+CD45low parameters [21]. The
ability of GIM to participate in innate immune function
was assessed by analyzing the surface expression of TLRs,
their ability to mediate tumor cytotoxicity, phagocytosis
and expression of FasL. Similar to findings in the murine
systems, GIM did express TLR, however GIM did not elab-
orate cytokines reflective of innate activation. In marked
contrast to findings within the murine system, GIM do
not express FasL. Furthermore, although GIM could medi-
ate non-MHC restricted cytotoxicity, microglia isolated
from normal brain were statistically more efficient at
tumor cytotoxicity. By characterizing the activation state
and functioning of GIM, we can not only comprehen-
sively identify their role in immune responses to human
gliomas, but we can also begin to develop ways in whichJournal of Translational Medicine 2006, 4:15 http://www.translational-medicine.com/content/4/1/15
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they can be manipulated to successfully design and opti-
mize immunotherapeutic strategies against malignant
brain tumors.
Methods
Human subjects
Patients' tumors (n = 50) were graded pathologically as
glioblastoma multiforme by a neuropathologist accord-
ing to the WHO classification [22,23]. Fresh normal brain
tissue (n = 6) can only be rarely obtained since for most
patients efforts are made by the neurosurgeon to preserve
this tissue. On occasion, normal brain tissue was obtained
during an approach to a benign tumor such as a sphenoid
wing meningioma, a well-circumscribed metastasis or a
low-grade lesion such as an oligodendroglioma. Addi-
tionally, peritumoral GBM tissue was also obtained and
separately analyzed, however because this tissue could
harbor microscopic tumor it was not characterized as nor-
mal for the purposes of this study. The resected normal tis-
sue demonstrated no evidence of increased signal on flair
MRI pre-operative imaging. The brain architecture was
inspected microscopically intraoperatively by an experi-
enced neurosurgeon (A.B.H.) and found to be consistent
with normal brain tissue prior to submission to the labo-
ratory. Peripheral blood was drawn from the patients
intraoperatively. This study was conducted under proto-
col # LAB03-0687, which was approved by the institu-
tional review board of The University of Texas M.D.
Anderson Cancer Center, and informed consent was
obtained.
Prioritization of characterization
Microglia could never be isolated in sufficient numbers
from a single GBM specimen to perform all of the assays
concurrently. Furthermore, there is significant variability
in the numbers of microglia obtained from each clinical
specimen that could not be predicted preoperatively. A
minimum of 5 grams of tissue was necessary in order to
isolate sufficient microglia for the basic phenotypic char-
acterizations. Purity was established on all specimens
regardless of the assay priority. Fresh surgical tissues were
analyzed as follows: 1) If a normal and GBM specimen
could be obtained simultaneously then priority went to
performing the cytotoxicity assays. In two years, this sce-
nario was very rare even at a hospital specializing in
neuro-oncological neurosurgery. Routinely drawn intra-
operative peripheral blood was accessed for the controls.
2) For specimens > 5 grams, the microglia were phenotyp-
ically and functionally characterized.
Isolation of microglia from human brain tumor tissue 
samples
Microglia were purified using modifications to an isola-
tion technique previously described [21] after evaluation
of the phenotype of each interphase. This technique min-
imized artificial activation of the microglia and these cells
were isolated usually within three hours of surgical resec-
tion. Briefly, after surgical resection, freshly isolated
tumor, peritumoral, or normal brain tissue was mechani-
cally dissociated through a stainless steel sieve. The disso-
ciated material was centrifuged and the pellet was washed.
Cells were layered onto an isotonic Percoll (Amersham
Biosciences, Uppsala, Sweden) gradient diluted to 1.095
g/mL and overlaid with 1.03 g/mL Percoll. After centrifu-
gation, the visible cell layer between the 1.095 g/mL and
1.03 g/mL layers was removed, washed, layered on top of
a second gradient (2-mL steps of isotonic Percoll diluted
to 1.12, 1.088, 1.072, 1.065, and 1.03 g/mL densities) and
centrifuged. Microglia were collected from the interface
between the 1.065 g/mL and 1.03 g/mL layers and
washed. Their viability was then determined by the
Trypan blue dye-exclusion method.
Antibodies
Cell surface staining was performed with phycoerythrin-
or fluorescein isothiocyanate-labeled antibodies against
the following proteins: CD11b, CD11c, CD16, CD32,
CD45, FasL (Pharmingen, San Diego, CA); and TLR-1, -2,
-3, and -4 (eBiosciences, San Diego, CA). For intracellular
cytokine staining, we used phycoerythrin- or fluorescein
isothiocyanate- labeled antibodies against TNF-α, IL-1β
and IL-6 (R&D Systems, Minneapolis, MN). Appropriate
isotype controls were used for every antibody.
Cell surface and intracellular cytokine marker staining
Microglia were Fc blocked for 20 minutes using purified
anti-CD16 antibody (Pharmingen). After washing, the
cells were incubated with the fluorescent-labeled primary
antibody or isotype control for 1 hour at 4°C. For the
intracellular cytokine analysis, microglia were fixed with
Cytofix/Cytoperm (BD Biosciences, San Jose, CA), washed
in PermWash (BD Biosciences), and then stained with flu-
orescence-labeled monoclonal antibodies or isotype con-
trols for 30 min at 4°C. Positive controls for all of the
monoclonal antibodies consisted of A375 cells (E. G.).
Approximately 1 × 104 live, gated events were assessed
during fluorescence-activated cell sorting using an Epics
XL-MCL cytometer (Beckman Coulter, Mountain View,
CA) and analyzed using IsoContour software (Verity Soft-
ware House, Topsham, ME).
Phagocytosis assay
Fluorescent-labeled polystyrene microparticles (0.99 µm;
Polysciences, 10 µL/tube) were coated with fetal bovine
serum (FBS) diluted to 50% in phosphate-buffered saline
and incubated with microglia (1 × 106/tube) for 30 min-
utes at 37°C. The reaction was stopped by the addition of
ice-cold phosphate-buffered saline. Cells were washed
and analyzed by fluorescence microscopy (Nikon E400,
Lewisville, TX) for internalized particles.Journal of Translational Medicine 2006, 4:15 http://www.translational-medicine.com/content/4/1/15
Page 4 of 9
(page number not for citation purposes)
Isolation of GIM and expression of surface markers demonstrating the purity of the GIM population (CD11b vs. CD45) at each  isolated fraction Figure 1
Isolation of GIM and expression of surface markers demonstrating the purity of the GIM population (CD11b vs. CD45) at each 
isolated fraction. Each interphase from the second percoll gradient was analyzed for expression of the surface markers CD11b 
and CD45. The gated cells in the upper right quadrant indicate the percentage of CD45+ gated cells that are also positive for 
CD11b and represent GIM. An autofluorescent population was identified in both normal and GBM tissue samples during flow 
cytometry analysis and is also consistently present in the respective isotype controls. This population was excluded when cal-
culating the percentages of positive fluorescing cells.
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Tumor cytotoxicity assay
1 to 2 × 106 U-87 MG (human malignant glioma) cells in
1 mL phosphate-buffered saline were labeled with 10 µL
of 100× carboxy-fluorescein diacetate succinimidyl ester
(CFSE, Cell Technology Inc., Minneapolis, MN) for 15
minutes at 24°C. The U-87 MG target cells were washed,
resuspended in phosphate-buffered saline with 10% FBS,
and incubated for 30 minutes at 37°C. Effector cells
(microglia or PBMCs) were isolated and added at varying
effector ratios to 1 × 105target cells. Cultures were incu-
bated for 4 hours or 24 hours, and 10 µL of 50 µg/mL pro-
pidium iodide was added to each culture before analysis
by FACSCalibur Instrumentation and CellQuest Pro soft-
ware (BD Biosciences, San Jose, CA).
Statistics
The intracellular cytokine data was analyzed by Exact
McNemars test for dichotomous categorical and matched
data. The in vitro cytotoxicity data were analyzed using the
Chi square test. The cutoff for statistical significance was P
< 0.05.
Results
Purity of microglia isolated from human gliomas
To determine the purity of our GIM isolation, cells were
stained with fluorescent-labeled antibodies to CD11b,
CD11c, and CD45, and the percentage of cells that were
CD11b/c+CD45low was determined using flow cytometry
(Fig. 1). We can isolate a CD45high  population from
peripheral blood, however, upon examining tumor
homogenates before Ficoll purification we fail to see a
CD11b/c+CD45high seen in the previous murine studies.
We observed the largest population of CD11b/c+CD45+
cells at the interphase between the 1.03 and 1.065, unlike
in the rodent studies where the interphase between the
1.065 and 1.072 gradients was identified to contain the
largest fraction of CD11b/c+CD45+ cells. The expression
levels of CD45 and CD11b/c were not significantly differ-
ent in the cells isolated from each interphase. Thus, in
contrast to the rodent purification of microglia/macro-
phages in which distinct CD11b/c+CD45high and CD11b/
c+CD45low cells were identified, we did not observe this
heterogeneity in any of our GBM or normal brain tumor
specimens. Our purified preparation was stained with
antibodies to CD3, CD4, CD8, and CD56 and was nega-
tive for contaminating cell populations, including lym-
phocytes and NK cells (data not shown).
The average yield of microglia isolated from human GBM
was 3.2 × 106 cells per gram of tumor (range: 1.8 × 105 -
3.7 × 107 cell/gram; n = 15) but was only 1.4 × 105 cells per
gram of normal brain (range 4.6 × 104 - 3 × 105; n = 5).
GIM express TLRs Figure 2
GIM express TLRs. GIM purity was determined as in Fig. 1 and the cells were double-stained for CD45 and TLRs. All CD45+ 
expressing cells were gated and observed for TLR expression. In each histogram, the data plot on the left indicates the isotype 
control, and the second plot represents CD45+ gated cells that expressed the respective TLR. These data are from one tumor 
specimen but are representative of at least five tumor tissue samples from human glioma patients.Journal of Translational Medicine 2006, 4:15 http://www.translational-medicine.com/content/4/1/15
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This represented an average, although highly variable,
30% recovery and a 60 fold-enrichment of the microglia.
The purity of GIM isolated from human glioma specimens
can vary due to disparities in each excised individual tis-
sue sample.
TLR expression on GIM
To determine whether GIM expressed the TLRs, we stained
our purified GIM with fluorescent-labeled antibodies to
TLR-1, -2, -3, and -4. Although TLR-1 was not expressed in
significant quantities, TLR-2, -3, and -4 were highly
expressed on GIM (n = 5) (Fig. 2). The TLR expression pro-
file was no different on microglia isolated from normal
brain (n = 3) (data not shown).
Cytokine expression by GIM
To determine if the microglia are activated within malig-
nant gliomas (n = 7) and participating in innate
responses, intracellular cytokine analysis was performed
for IL-1β, IL-6, and TNF-α. GIM failed to produce any sig-
nificant levels of these cytokines when compared to con-
trol cells (A375) and was no different from microglia
isolated from normal brain tissue (n = 3) (Fig. 3, Table 1).
GIM are functionally capable of phagocytosis
To determine whether GIM isolated from malignant glio-
mas were capable of mediating phagocytosis, GIM were
incubated with opsonized fluorescent beads. GIM showed
marked intracellular staining by the beads, indicating that
phagocytosis was not impaired in GIM despite the immu-
nosuppressive environment of gliomas (Fig. 4A). In con-
trast, control tumor cells bound the beads only on the
surface of the cell (Fig. 4B).
GIM can mediate non-MHC restricted anti-tumor cellular 
cytotoxicity
To ascertain whether GIM can mediate anti-tumor cyto-
toxicity, freshly isolated GIM were incubated as effectors
with U-87 MG target cells (a cell line derived from malig-
nant human glioma) at various effector-to-target ratios. As
controls, microglia from normal brain tissue and PBMCs
from the patient were incubated with U-87 MG cells in
similar ratios. All effector cells were unstimulated before
the assay and did not show significant cytotoxic activity
after 4 hours (data not shown). After 24 hours, even at a
1:10 effector:target ratio, GIM were functional in their
tumor cytotoxic activity (48.3% cells; 95% CI, 46.8-49.9)
and comparable to PBMCs (46.9% cells; 95%CI, 45.5-
48.2), however cytotoxic activity of GIM was significantly
(p < 0.0001) lower than that of microglia isolated from
normal brain tissue (72.4% cells; 95% CI, 69.7-75.0)(Fig.
5). We were not able to generate sufficient numbers of
GIM do not secret innate cytokines Figure 3
GIM do not secret innate cytokines. GIM purity was determined as in Fig. 1 and the cells were stained for intracellular 
cytokines IFN-α, IL-6, TNF-α. In each histogram, the data plot on the left indicates the isotype control, and the second plot 
represents respective cytokine producing cells. These data are from one tumor specimen but are representative of seven 
tumor tissue samples from human glioma patients and A375 control cells.
Isotype Isotype 0% Isotype 0%
GBM
IFN-D TNF-D IL-6
Table 1: Distribution of cytokine production by glioma 
infiltrating microglia from 7 representative human glioma 
patients. Positive intracellular staining was confirmed for all 
cytokines by either a reporter cell line (A375).
Pathology IL-1β IL-6 TNF-α 
GBM 0% 0% 0%
GBM 0% 0% 0%
GBM 0% 0% 0%
GBM 0% 0% 0%
GBM 0% 0% 0%
AA 0% 0% 0%
AA 0% 0% 0%
Normal 0% 0% 0%
Normal 0% 0% 0%
Normal 0% 2% 0%
A375 58% 3% 5%
Percentages indicate CD11b+CD45+ GIM gated on all CD45+ cells and 
are adjusted to that of corresponding isotype controls.
Abbreviations: IL, interleukin; TNF, tumor necrosis factor; GBM, 
glioblastoma multiforme; AA, anaplastic astrocytoma.Journal of Translational Medicine 2006, 4:15 http://www.translational-medicine.com/content/4/1/15
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microglia from normal brain tissue to test higher effec-
tor:target ratios.
Microglia express fas ligand at low levels
To ascertain whether human GIM were preventing antitu-
mor T cell activity via Fas-FasL-mediated apoptosis of T
cells, the GIM were stained with an anti-FasL antibody. In
contrast to the murine findings, human GIM did not
express FasL or expressed it at very low levels (n = 11)(Fig.
6), indicating that Fas-FasL-mediated apoptosis is not a
predominant mechanism of immune evasion by GIM in
humans.
Discussion and conclusion
This study evaluates for the first time the innate immuno-
logic phenotype and function of human microglia iso-
lated from brain tumors. Activation of innate immunity
triggers the subsequent activation of adaptive immune
response [24,25] that are essential for tumor eradication/
suppression. An ongoing debate is whether the immune
system can recognize the presence of a tumor. Although it
has been argued that tumors fail to provide sufficient pro-
inflammatory responses, others have recently suggested
otherwise [26,27]. Mechanisms that induce innate
immune responses similar to microbial pathogens
include dying cells producing uric acid [28]; heat shock
proteins [29-31]; and extracellular matrix derivatives,
such as hyaluronic acid [32] or heparin sulfates [33],
which are all TLR-4 agonists. All these materials are prodi-
giously produced by gliomas [34-37] indicating that
innate immunity can be potentially activated by these gli-
oma factors. Our data shows that similar to the murine
system [16], there is TLR expression on the GIM. The inter-
action of the microglia with TLR agonists should lead to
the induction of a plethora of inflammatory mediators,
such as TNF-α, IL-1 and IL-6. These cytokines subse-
quently induce the local inflammatory response. How-
ever, none of these cytokines were produced by the
microglia within the immunosuppressive microenviron-
ment of the malignant glioma. It is important to note that,
unlike the phagocytosis of pathogens that is followed by
the induction of inflammatory mediators, phagocytosis of
apoptotic and senescent cells is immunologically silent
and does not lead to the induction of inflammatory
responses. Thus, despite the elaboration of factors such as
heat shock proteins and hyaluronic acid that could acti-
vate innate immunity on microglia, the "balance" of
micro-environmental influences including apoptotic gli-
oma cells and immunosuppressive cytokines impede
innate immune activation as reflected by cytokine produc-
tion.
GIM can participate in the initial steps of innate immunity
since they are capable of phagocytosis. However, due to
the limitations in obtaining normal brain tissue, we can-
not discount the possibility that this phagocytic ability of
GIM might be impaired when compared to that of micro-
glia isolated from normal brain. Indeed we find that GIM,
while capable of non-MHC mediated cytotoxicity, they
are significantly less able to participate in tumor cytotoxic
activity compared to normal microglia. The direct cytotox-
icity of GIM against tumor cells is tempered by the fact
that immunosuppressive cytokines/factors that influence
the function of GIM are withdrawn for 24 hours. How-
ever, the U-87 glioma cell line secretes the immunosup-
GIM can mediate phagocytosis Figure 4
GIM can mediate phagocytosis. Cells were incubated with 
opsonized fluorescent beads and analyzed using fluorescence 
microscopy at 20× magnification. A, GIM containing phagocy-
tosed beads. B, Control tumor cell that has fluorescent beads 
sticking to the surface but not internalized. Cells were ana-
lyzed through a z-stack to determine whether the beads 
were internalized or merely on the surface.
b. a. GBM tumor cell GIM
GIM cannot initiate Fas-mediated apoptosis Figure 6
GIM cannot initiate Fas-mediated apoptosis. The histogram is 
depicted similar to that in Fig. 2. GIM were gated on CD45+ 
expression and were analyzed for expression of FasL. These 
data are from one tumor specimen and are representative of 
at least 11 tumor tissue samples from human glioma patients.Journal of Translational Medicine 2006, 4:15 http://www.translational-medicine.com/content/4/1/15
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pressive cytokine TGF-β, in part recapitulating the in vivo
scenario. In vivo cytokines such as IL-10 prevent macro-
phages from becoming tumoricidal by inhibiting the pro-
duction of TNF and nitric oxide. Because the assay
requires 24 hours, the effects of the tumor microenviron-
ment are in part withdrawn while the assay is in progress.
Thus, the relative ability of GIM compared to normal
microglia to mediate cytotoxicity may be even more pro-
found in vivo.
The role of FasL within innate immunologic responses is
not straightforward. For example, when tumors express
soluble FasL, immunologic responses appear to be sup-
pressed. However, when FasL is expressed in a membrane-
bound form, neutrophil-mediated inflammation is
induced, and both the innate and adaptive immune sys-
tems are activated [17]. Contradictory results have dem-
onstrated that high levels of expression of FasL can
inactivate neutrophils [19]. Murine microglia have previ-
ously been reported as expressing FasL [20]. We wanted to
determine whether FasL was similarly a potential immu-
notherapy target in human GIM; however, we did not find
any significant expression of FasL on microglia across a
wide array of grades of gliomas and metastatic cancers.
Therefore, modulating techniques directed at FasL on
human GIM are not likely to be successful. However, this
does not rule out a potential immunological benefit of
modulating FasL on the tumor cells.
This study is the first to our knowledge to characterize
immune activation at the level of the innate arm on
microglia in glioma patients. Of course, we cannot
exclude the possibilities that activation of the innate
immune system could occur on another CNS cells beside
microglia or that innate immune activation could occur
via draining TLR agonists to the cervical lymph nodes. The
activation of innate immunity on GIM through select
TLRs may be a future approach to enhancing the incorpo-
ration and activation of adaptive immune responses, but
a careful screening through the panel of agonists will be
necessary because not all TLR agonists may cause activa-
tion, especially in the presence of immunosuppressive
cytokines/factors. While it is important to further charac-
terize these innate functions and understand the role they
play in anti-tumor immune responses, our data appears to
demonstrate that some of the innate immune functions
remain unaffected despite the immunosuppressive gli-
oma environment and can perhaps be manipulated to
develop effective immunotherapeutic responses to glio-
mas.
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